Category: Merck Millipore
Dr. Martin Madaus, the former CEO of Millipore, is stepping away from Covidien's board to become the CEO of an unnamed company.
Covidien (NYSE:COV) said Dr. Martin Madaus will step down from its board of directors to take an open CEO position with a privately-owned company.
Shares of Misonix gain 19% on Wall Street today after the medical device company reports a swing to 4th-quarter and full-year black.
Misonix (NSDQ:MSON) shares are up 19% today after the medical device company swung to black ink for its fiscal 4th quarter and full year.
Farmingdale, N.Y.-based Misonix posted profits of $366,000, or 5¢ per share, on sales of $1.7 million for the 12 months ended June 30 – for a 26.7% top-line gain that helped Misonix swing from a $3.5 million loss during its last fiscal year.
German chemical and drug company Merck KGaA forecasts profit growth of up to 45 percent in 2011 as its post-merger Merck Millipore unit forecasts revenue growth of up to 56 percent.
Recently acquired Millipore pumped nearly $900 million in additional revenues into Merck Group KGaA (XETRA:MRK) during the second half of 2010, including a $465 million, fourth-quarter contribution.